Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1997;30:1009-1014

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimosawa, T.
Right arrow Articles by Fujita, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimosawa, T.
Right arrow Articles by Fujita, T.

(Hypertension. 1997;30:1009-1014.)
© 1997 American Heart Association, Inc.


Articles

A Newly Identified Peptide, Proadrenomedullin N-Terminal 20 Peptide, Induces Hypotensive Action via Pertussis Toxin–Sensitive Mechanisms

Tatsuo Shimosawa; Katsuyuki Ando; Toshiro Fujita

From the Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Tokyo 112, Japan.

Correspondence to Toshiro Fujita, MD, Fourth Department of Internal Medicine, University of Tokyo School of Medicine, 3-28-6 Mejirodai Bunkyo-ku, Tokyo 112, Japan. E-mail fujita-dis{at}h.u-tokyo.ac.jp

Abstract Proadrenomedullin N-terminal 20 peptide (PAMP) and adrenomedullin (AM) are novel hypotensive peptides. Although they are derived from the same gene product, proadrenomedullin, their hypotensive mechanisms are different; PAMP inhibits the release of norepinephrine from the peripheral sympathetic nerve endings, whereas AM fosters vasodilation by elevating intracellular cAMP, possibly via activation of cholera toxin–sensitive G proteins. In PC12 cells, PAMP inhibited N-type calcium channel via activation of pertussis toxin–sensitive mechanisms. To clarify the relationship between the hypotensive effect of PAMP and pertussis toxin-sensitive mechanisms, we administered pertussis vaccine intraperitoneally into rats for 3 consecutive days. By using mesenteric artery preparation, we showed that PAMP's ability to decrease norepinephrine overflow was significantly attenuated in pertussis toxin-treated rat (-18.5±6.9%; P<.05 versus control rats). In electrically stimulated pithed rat, PAMP (20 and 40 nmol/kg) showed a hypotensive effect (-13±5 and -18±7 mm Hg, respectively; P<.05, P<.01), whereas in pertussis vaccine-treated rat it did not (-2±3 and -8±9 mm Hg, respectively; P=NS). Also, in pithed rat, plasma norepinephrine level was significantly elevated by electrical stimulation in both control (0.323±0.035 ng/mL) and pertussis vaccine- treated groups (0.355±0.079 ng/mL). After injection of PAMP (40 nmol/kg), plasma norepinephrine level significantly decreased in the control group (0.225±0.044 ng/mL; P<.01) but not in the pertussis vaccine-treated group (0.392±0.021 ng/mL; P=NS). Moreover, in conscious rats, intravenous administration of PAMP (40 nmol/kg) did not evoke hypotension after pertussis vaccine treatment, although untreated controls had significantly decreased arterial pressure (-5±2 versus -20±3 mm Hg; P<.01). In contrast to PAMP, the administration of AM (1 nmol/kg) significantly reduced the blood pressure of pertussis vaccine-treated as well as control rats (-20±5 versus -18±7 mm Hg; P=NS). These results demonstrate that the ability of PAMP to inhibit norepinephrine release from peripheral sympathetic nerve endings and to decrease blood pressure is pertussis toxin sensitive. Our findings thus suggest that despite being derived from the same gene, PAMP and AM apparently produce hypotension by activating different signaling pathways.


Key Words: sympathetic nervous sytem • pertussis vaccine • rats • norepinephrine




This article has been cited by other articles:


Home page
EndocrinologyHome page
A. Martinez, J. A. Bengoechea, and F. Cuttitta
Molecular Evolution of Proadrenomedullin N-Terminal 20 Peptide (PAMP): Evidence for Gene Co-Option
Endocrinology, July 1, 2006; 147(7): 3457 - 3461.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Shimosawa, T. Ogihara, H. Matsui, T. Asano, K. Ando, and T. Fujita
Deficiency of Adrenomedullin Induces Insulin Resistance by Increasing Oxidative Stress
Hypertension, May 1, 2003; 41(5): 1080 - 1085.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. S. Belloni, G. P. Rossi, P. G. Andreis, F. Aragona, H. C. Champion, P. J. Kadowitz, W. A. Murphy, D. H. Coy, and G. G. Nussdorfer
Proadrenomedullin N-Terminal 20 Peptide (PAMP), Acting Through PAMP(12–20)-Sensitive Receptors, Inhibits Ca2+-Dependent, Agonist-Stimulated Secretion of Human Adrenal Glands
Hypertension, May 1, 1999; 33(5): 1185 - 1189.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Mahata, S. K. Mahata, R. J. Parmer, and D. T. O'Connor
Proadrenomedullin N-Terminal 20 Peptide : Minimal Active Region to Regulate Nicotinic Receptors
Hypertension, November 1, 1998; 32(5): 907 - 916.
[Abstract] [Full Text] [PDF]